Workflow
CHALKIS(000972)
icon
Search documents
中基健康(000972) - 2021 Q4 - 年度财报
2022-07-08 16:00
Financial Performance - The company's operating revenue for 2021 was approximately ¥174.45 million, representing a 659.61% increase compared to ¥22.97 million in 2020[19]. - The net profit attributable to shareholders for 2021 was a loss of approximately ¥106.81 million, an improvement from a loss of ¥265.89 million in 2020[19]. - The net cash flow from operating activities for 2021 was a negative ¥188.67 million, compared to a negative ¥9.89 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥676.04 million, a 16.06% increase from ¥582.51 million at the end of 2020[19]. - The net assets attributable to shareholders decreased by 60.68% to approximately ¥69.23 million at the end of 2021, down from ¥176.04 million at the end of 2020[19]. - The basic earnings per share for 2021 was -¥0.14, an improvement from -¥0.34 in 2020[19]. - The weighted average return on net assets for 2021 was -87.10%, slightly worse than -86.05% in 2020[19]. - The company achieved total operating revenue of CNY 174.45 million in 2021, a significant increase from CNY 22.97 million in 2020[20]. - The net profit attributable to shareholders was CNY -106.81 million in 2021, compared to CNY -10.68 million in 2020[29]. - The gross profit margin for the manufacturing sector was 2.38%, with total operating costs amounting to ¥155,157,837.74[39]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 15%[76]. - The company reported a total revenue of 10,000 million in 2021, with a significant increase of 1,700 million compared to the previous year[77]. - The company reported a net profit of -106,874,713.82 CNY for the year 2021, with a net profit attributable to shareholders of the parent company at -106,814,799.25 CNY[179]. Operational Activities - The company produced over 58,000 tons of bulk tomato sauce during the production period from August 8 to September 30, 2021, equivalent to 72,000 tons of standard sauce[31]. - The company sold 30,058.06 tons of bulk tomato sauce in 2021, with a production volume of 58,282.83 tons and an ending inventory of 28,224.78 tons[40]. - The company has resumed production of high-value tomato lycopene health products to optimize its product structure[34]. - The company has resumed production of large-packaged tomato sauce after a halt due to market conditions, ensuring the continuity of its main business[52]. - The company has fully restored its tomato industry production, with a focus on high-value tomato products and small-packaged tomato sauce, aiming to strengthen its "red industry" [65]. - The company plans to produce 80,000 tons of large-packaged tomato sauce and 200,000 bottles of lycopene in 2022[64]. Market and Strategic Initiatives - The company plans to enhance its market operations and cost management to improve the financial status of the tomato industry[29]. - The company is focusing on integrating and optimizing resources to reduce operational burdens through leasing arrangements[30]. - The company is exploring long-term incentive mechanisms and employee stock ownership to ensure sustainable development [65]. - The company aims to leverage capital market financing and restructuring effects to increase resilience and create new profit growth points [66]. - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products and technologies were not detailed in the report[79]. - The company has completed a strategic acquisition of a smaller competitor for 300 million, expected to enhance market share[76]. - Market expansion plans include entering three new international markets by the end of 2022[76]. Financial Position and Liabilities - The company's fixed assets decreased by 14.2% from ¥354,399,017.09 at the beginning of the year to ¥315,290,506.46 at the end of the year[55]. - The company's inventory increased to ¥160,812,447.35, representing 23.79% of total assets[55]. - The company has set aside over 24 million yuan to address the debt issue from the bankruptcy proceedings of its former subsidiary, with a repayment ratio of 10.14%[128]. - The company has a frozen bank account balance of RMB 9,377.65 and RMB 3,362.29 in two different accounts[134]. - The company was ordered to pay a total of RMB 124,628,370.62, which includes principal, appraisal fees, and court costs[134]. - A contingent liability of 123,970,926.36 CNY was recognized related to a legal dispute with Xinjiang Jinseng Hu Yang Asset Management Co., Ltd.[184]. Governance and Compliance - The company has established a complete independent governance structure, ensuring compliance with relevant laws and regulations [71]. - The company maintains independence from its controlling shareholders in business, personnel, assets, organization, and finance [72]. - The company has implemented a training mechanism for employees, focusing on leadership and general skills development[103]. - The company conducted a self-inspection of corporate governance in accordance with regulatory requirements[112]. - The company has retained its accounting firm for seven years, with an audit fee of 1.2 million yuan for the current period[125]. - The audit opinion issued was a qualified opinion with a significant uncertainty regarding the company's ability to continue as a going concern[177]. Human Resources - The total number of employees at the end of the reporting period is 149, with 28 in the parent company and 121 in major subsidiaries[101]. - The professional composition includes 83 production personnel, 20 financial personnel, and 22 administrative personnel, among others[101]. - The educational background of employees shows 2 with postgraduate degrees, 19 with bachelor's degrees, and 61 with associate degrees[101]. - The company has established a performance evaluation and incentive mechanism based on a transparent salary system[102]. Environmental and Social Responsibility - The company is not classified as a key pollutant discharge unit and has not faced any administrative penalties related to environmental issues during the reporting period[115]. - The company has implemented measures to reduce carbon emissions, including energy-saving initiatives and improvements in energy utilization and wastewater treatment capabilities[115]. - The company has a commitment to social responsibility, focusing on poverty alleviation and regional economic growth, contributing to local agricultural development and farmers' income[116].
中基健康(000972) - 2021 Q4 - 年度财报
2022-05-27 16:00
Financial Performance - The company's operating revenue for 2021 was approximately ¥174.45 million, representing a 659.61% increase compared to ¥22.97 million in 2020[19]. - The net profit attributable to shareholders for 2021 was a loss of approximately ¥100.52 million, an improvement from a loss of ¥265.89 million in 2020[19]. - The net cash flow from operating activities for 2021 was a negative ¥188.67 million, compared to a negative ¥9.89 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥682.34 million, an increase of 17.14% from ¥582.51 million at the end of 2020[19]. - The net assets attributable to shareholders decreased by 57.10% to approximately ¥75.52 million at the end of 2021 from ¥176.04 million at the end of 2020[19]. - The basic earnings per share for 2021 was -¥0.13, an improvement from -¥0.34 in 2020[19]. - The weighted average return on net assets for 2021 was -79.92%, a decrease of 6.13 percentage points from -86.05% in 2020[19]. - The company reported a net profit of -100,580,101.65 CNY for the year 2021, with a net profit attributable to shareholders of -100,520,187.08 CNY[175]. - The net loss for 2021 was CNY 100,580,101.65, compared to a net loss of CNY 266,724,598.87 in 2020, showing an improvement of approximately 62.3%[200]. Revenue and Sales - The company achieved total operating revenue of CNY 174.45 million in 2021, a significant increase from CNY 22.97 million in 2020[20]. - The total revenue for 2021 reached ¥174,451,612.86, representing a significant increase of 659.61% compared to ¥22,966,067.61 in 2020[36]. - The manufacturing sector contributed ¥165,753,883.70, accounting for 95.01% of total revenue, while rental services generated ¥7,987,472.83, a decrease of 65.09% year-over-year[36]. - The major product, bulk tomato sauce, generated revenue of ¥158,933,143.77, which is 91.10% of total revenue[36]. - Total sales amount from the top five customers reached ¥173,488,896.02, accounting for 99.44% of the annual sales[47]. Production and Operations - The company produced over 58,000 tons of bulk tomato sauce during the production period from August 8 to September 30, 2021, equivalent to 72,000 tons of standard sauce[31]. - The company produced over 58,282.83 tons of bulk tomato sauce in 2021, with a sales volume of 30,058.06 tons[40]. - The company has resumed production of high-value tomato lycopene health products to optimize its product structure[34]. - The company operates under a "leading enterprise + base + farmers" model to ensure stable raw material procurement[34]. - The company has fully restored its tomato industry production, optimizing the product structure and resuming the production of high-value tomato lycopene health products and small-packaged tomato sauce[65]. Cash Flow and Assets - The company reported a net cash flow from operating activities of CNY 72.15 million in the fourth quarter, following a negative cash flow in the previous quarters[24]. - Operating cash inflow totaled ¥170,591,574.35, a significant increase of 509.16% year-on-year[51]. - Operating cash outflow reached ¥359,266,256.30, an increase of 848.10% compared to the previous year[51]. - The company's inventory increased to ¥160,812,447.35, representing 23.57% of total assets[55]. - Fixed assets decreased to ¥315,290,506.46, accounting for 46.21% of total assets, down 14.63%[55]. Future Plans and Strategies - The company plans to apply for the removal of the delisting risk warning after the 2021 annual report disclosure, but the approval remains uncertain[5]. - The company plans to produce 80,000 tons of large-pack tomato sauce and 200,000 bottles of lycopene in the upcoming year[64]. - The company aims to achieve profitability in 2022 after a period of losses[64]. - The company is focusing on integrating and optimizing resources to reduce operational burdens through leasing arrangements[30]. - The company plans to enhance its market-oriented operational mechanism and improve cost management to boost the profitability of its tomato industry[29]. Governance and Management - The total remuneration for directors, supervisors, and senior management was CNY 1.7465 million (including tax) for the year ended December 31, 2021[90]. - The company has established a complete independent governance structure, ensuring separation from its controlling shareholder in business, personnel, assets, organization, and finance[72]. - The company is focused on maintaining transparency in its remuneration practices and ensuring compliance with relevant regulations[90]. - The company held multiple board meetings during the reporting period, including the third and fourth meetings of the eighth board and several temporary meetings, with key resolutions passed regarding the 2020 annual report and financial statements[93]. Legal and Compliance Issues - The company reported a negative net profit for the year, leading to a "delisting risk warning" from the Shenzhen Stock Exchange due to revenues falling below 100 million yuan[124]. - The company has been ordered to pay a total of RMB 124,628,370.62, which includes principal, fees, and other costs related to a legal dispute[130]. - The company has frozen assets including RMB 123,970,926.36 in deposits and dividends from its subsidiary, Xinjiang Zhongji Red Tomato Industry Co., Ltd., for a period of three years[130]. - The company has engaged a professional institution for asset evaluation related to debt compensation[133]. Social Responsibility and Environmental Impact - The company is recognized as a key agricultural industrialization enterprise and has contributed to local economic development and poverty alleviation efforts in the Xinjiang region[115]. - The company has implemented measures to reduce carbon emissions, focusing on energy conservation and enhancing wastewater treatment capabilities[113]. - The company is committed to fulfilling its social responsibilities and has established a system to regularly evaluate its social responsibility practices[114].
中基健康(000972) - 2022 Q1 - 季度财报
2022-04-26 16:00
Financial Performance - The company's operating revenue for Q1 2022 was CNY 24,893,658.36, a 100.00% increase compared to the same period last year when it was CNY 0.00[3] - The net profit attributable to shareholders was a loss of CNY 4,986,755.44, an improvement from a loss of CNY 19,979,751.27 in the previous year, representing a 75.01% reduction in losses[3] - The net profit for the first quarter of 2022 was -4,995,605.10 RMB, compared to -19,988,180.25 RMB in the same period last year, showing an improvement of approximately 75%[18] - The total comprehensive income attributable to the parent company was -4,986,755.44 RMB, compared to -19,979,751.27 RMB in the previous year, indicating a significant reduction in losses[19] - The basic and diluted earnings per share were both -0.0065, an improvement from -0.0259 in the prior year[19] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 42,976,551.37, compared to a negative cash flow of CNY 25,390,802.51 in the same period last year[3] - Cash inflows from operating activities totaled 66,639,447.85 RMB, a substantial increase from 149,553.82 RMB in the same period last year[20] - Cash and cash equivalents at the end of the period amounted to 63,204,247.88 RMB, up from 10,548,551.53 RMB at the end of the previous year[21] - The company's cash and cash equivalents increased to CNY 63,204,247.88 from CNY 20,517,341.41 at the beginning of the year, representing a growth of approximately 207.5%[13] Assets and Liabilities - Total assets at the end of the reporting period were CNY 705,638,598.38, reflecting a 3.42% increase from CNY 682,336,138.44 at the end of the previous year[3] - Total liabilities rose to CNY 630,002,798.51 from CNY 601,705,050.46, an increase of approximately 4.7%[15] - The total equity attributable to shareholders decreased to CNY 70,537,058.61 from CNY 75,523,652.38, a decline of about 6.5%[16] Operating Costs and Expenses - Total operating costs for Q1 2022 amounted to CNY 30,042,866.00, an increase from CNY 20,017,428.02 in the previous year[17] - The company reported operating expenses of 23,662,896.48 RMB, slightly lower than 25,540,356.33 RMB in the previous year[20] - The company's management expenses decreased by 63.89% to CNY 6,739,952.29 from CNY 18,666,259.97 in the previous year due to reduced operational costs[7] Taxation and Subsidies - The company reported a 1820.85% increase in taxes and surcharges, amounting to CNY 116,403.27, compared to CNY 6,060.00 in the previous year[7] - The company received government subsidies amounting to CNY 89,218.29, marking a 100.00% increase from CNY 0.00 in the previous year[7] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,338[10] Inventory and Receivables - Accounts receivable decreased to CNY 126,855,321.23 from CNY 135,604,961.65, a decline of about 6.0%[13] - Inventory decreased to CNY 151,678,614.40 from CNY 160,812,447.35, reflecting a reduction of approximately 5.7%[14] Research and Development - The company incurred research and development expenses of CNY 458.49, with no expenses reported in the same period last year[17] Other Information - The company did not report any significant new product developments or market expansions during this quarter[22]
中基健康(000972) - 2021 Q4 - 年度财报
2022-03-25 16:00
Financial Performance - The company's operating revenue for 2021 was approximately ¥174.45 million, representing a 659.61% increase compared to ¥22.97 million in 2020[19]. - The net profit attributable to shareholders for 2021 was a loss of approximately ¥100.52 million, an improvement from a loss of ¥265.89 million in 2020[19]. - The net cash flow from operating activities for 2021 was a negative ¥188.67 million, compared to a negative ¥9.89 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥682.34 million, an increase of 17.14% from ¥582.51 million at the end of 2020[19]. - The net assets attributable to shareholders decreased by 57.10% to approximately ¥75.52 million at the end of 2021 from ¥176.04 million at the end of 2020[19]. - The basic earnings per share for 2021 was -¥0.13, an improvement from -¥0.34 in 2020[19]. - The weighted average return on net assets for 2021 was -79.92%, a decrease of 6.13 percentage points from -86.05% in 2020[19]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 15%[75]. - The company reported a total revenue of 11,700 million in 2021, with a significant increase compared to the previous year[76]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year increase of 20%[82]. - The total comprehensive loss for 2021 was CNY -100,580,101.65, compared to CNY -266,724,598.87 in 2020, indicating a reduction of approximately 62.3%[197]. Operational Highlights - The company produced over 58,000 tons of bulk tomato sauce during the production period from August 8 to September 30, 2021[31]. - The company resumed production of high-value tomato lycopene health products to optimize its product structure[34]. - The company maintained a seasonal production cycle for fresh tomatoes, with the harvesting period from early August to the end of September[34]. - The company has fully restored its tomato industry production, optimizing the product structure to include high-value tomato lycopene health products and small-packaged tomato sauce[64]. - The company plans to produce 80,000 tons of large-packaged tomato sauce and 200,000 bottles of lycopene in the upcoming year[63]. - The company has signed a contract for the leasing of tomato harvesting machines to alleviate financial pressure and reduce costs[30]. - The company has engaged in multiple investor communications, receiving over 300 inquiries via phone and 107 written inquiries during the reporting period[67]. Strategic Initiatives - The company plans to enhance its market-oriented operational mechanism and improve cost management to boost profitability in the tomato industry[29]. - The company is focusing on improving its corporate governance structure and exploring long-term incentive mechanisms to ensure sustainable development[64]. - The company is actively exploring market expansion opportunities to enhance its core competitiveness and profitability[65]. - The company is committed to utilizing capital market financing and restructuring effects to increase its resilience and create new profit growth points[65]. - The company has established a post-doctoral research workstation to enhance its technological innovation capabilities[32]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[80]. Governance and Management - The company has established a complete independent governance structure, ensuring operational independence from its controlling shareholders[71]. - The company is focused on maintaining a transparent remuneration policy for its executives[90]. - The total remuneration for directors, supervisors, and senior management was 1.7465 million yuan (including tax) as of December 31, 2021[90]. - The company has a structured salary management system for determining the remuneration of its directors and senior management[90]. - The company has appointed new board members with diverse backgrounds and experiences to strengthen its management team[79]. - The company has implemented a training mechanism for employees, focusing on various levels of management and general staff[102]. Risks and Challenges - The company has faced continuous operating capability uncertainties as indicated in the audit report for the recent year[19]. - The company is facing risks related to adverse weather conditions in Xinjiang, which could impact tomato yield and quality, thus affecting production and operational stability[65]. - The audit opinion highlighted a significant uncertainty regarding the company's ability to continue as a going concern, raising concerns about its financial stability[172]. - The company is closely monitoring the ongoing legal proceedings and their potential impacts on its operations[132]. Legal and Compliance - The company has not faced any penalties from securities regulatory authorities for its current and recently departed directors, supervisors, and senior management[88]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[120]. - The company has initiated a lawsuit against the execution objection, with the court ruling on May 20, 2020, rejecting the plaintiff's request for 123,970,926.36 yuan[128]. - The company has frozen bank accounts with a total amount of 12,739.71 yuan, including 9,377.65 yuan at China Merchants Bank and 3,362.29 yuan at Xinjiang Urumqi Rural Commercial Bank[130]. Future Outlook - The company projects a revenue growth of 10% for the next fiscal year, targeting 1.65 billion in total revenue[75]. - New product launches are expected to contribute an additional 200 million in revenue in the upcoming year[75]. - The company aims to turn losses into profits as part of its operational goals for 2022[63]. - The company anticipates a positive outlook for future performance, driven by strategic growth initiatives and market expansion efforts[76].
中基健康(000972) - 2020 Q3 - 季度财报
2021-10-28 16:00
Financial Performance - Operating revenue for the reporting period was CNY 42,964,683.12, an increase of 5,271.56% year-on-year[8] - Net profit attributable to shareholders of the listed company was CNY 2,667,106.83, with a year-to-date loss of CNY 42,077,086.68[8] - Basic earnings per share for the reporting period were CNY 0.003, compared to a loss of CNY 0.0546 in the same period last year[8] - The weighted average return on net assets was 0.61%, an increase of 1.76 percentage points year-on-year[8] - The company reported a net loss attributable to shareholders of ¥42,077,086.68, a decrease of 284.06% from a profit of ¥22,860,511.96 in the previous period[15] - The total comprehensive income decreased by 285.52% to -¥42,112,313.51 from ¥22,699,015.33, reflecting the overall financial downturn[15] - The company reported a net loss in retained earnings, increasing from CNY -1,437,437,657.71 to CNY -1,479,549,971.22, indicating a worsening of approximately 2.9%[33] - The company reported a net loss of CNY 42,112,313.51 for Q3 2020, compared to a net profit of CNY 22,699,015.33 in the same period last year, indicating a significant decline in profitability[48] - The total profit for the period was CNY -42,158,034.04, contrasting with a profit of CNY 23,365,182.52 in the prior year, highlighting a drastic shift in financial performance[48] Assets and Liabilities - Total assets at the end of the reporting period were CNY 669,410,187.63, a decrease of 9.57% compared to the end of the previous year[8] - Net assets attributable to shareholders of the listed company were CNY 399,819,294.00, down 9.53% from the previous year[8] - Current assets decreased from CNY 336,301,718.81 to CNY 298,480,266.42, a reduction of about 11.3%[30] - Total liabilities decreased from CNY 292,346,652.15 to CNY 263,554,151.72, a decline of about 9.8%[32] - Non-current assets decreased from CNY 403,980,721.84 to CNY 370,929,921.21, a decline of about 8.2%[31] - The total equity attributable to shareholders decreased from CNY 441,936,607.51 to CNY 399,819,294.00, a reduction of approximately 9.5%[33] Cash Flow - The company reported a net cash flow from operating activities of CNY -1,669,475.90 for the reporting period[8] - The company's cash and cash equivalents decreased by 66.96% to ¥26,646,992.28 from ¥80,644,820.58 due to business transformation and debt repayment[15] - Cash flow from operating activities showed a net outflow of CNY -2,897,879.20, a significant decrease from a net inflow of CNY 54,803,106.71 in the same quarter last year[53] - The company received cash related to operating activities of ¥50,001,448.33, an increase of 91.26% from ¥26,143,150.72, indicating improved cash flow from operations[16] - The cash flow from investment activities showed a net outflow of -5,008,000.00 CNY, contrasting with a net inflow of 68,935,364.09 CNY in the previous period[58] - Cash flow from financing activities resulted in a net outflow of -48,005,077.36 CNY, compared to -120,469,078.30 CNY in the previous period, indicating improved cash management[58] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,141[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., held 16.18% of the shares[11] Business Transformation and Strategy - The company plans to issue shares to raise funds for the modernization of traditional Chinese medicine and emergency medical supplies production, which will change its main business focus[17] - The company is focusing on market expansion and new product development as part of its strategic initiatives, although specific details were not disclosed in the report[48] - The company has not engaged in any securities or derivative investments during the reporting period[19][20] Operational Costs and Expenses - The total operating costs for the year-to-date were 70,506,467.43, compared to 232,818,833.74 in the previous year[47] - Management expenses increased to CNY 36,853,759.11 from CNY 29,580,073.59, indicating rising operational costs[48] - Research and development expenses for the third quarter amounted to 10,179,080.15, indicating ongoing investment in innovation[40] - Research and development expenses amounted to CNY 11,721,700.00, indicating ongoing investment in innovation despite financial losses[48] Other Financial Metrics - The company recorded other income of CNY 178,736.58, which was lower than the previous year's CNY 374,068.77, suggesting reduced ancillary income sources[48] - The company reported a credit impairment loss of -5,498,845.88 for the third quarter, reflecting challenges in asset quality[40] - The company incurred a credit impairment loss of CNY -16,521,669.99, which negatively impacted overall profitability[48] - There were no non-recurring gains or losses reported during the reporting period[8] Future Reporting and Standards - The company has not yet audited the third-quarter report, which may affect the reliability of the financial data presented[59] - The company is implementing new revenue and leasing standards starting in 2020, which may impact future financial reporting[59]
中基健康(000972) - 2020 Q1 - 季度财报
2021-10-28 16:00
Financial Performance - The company's operating revenue for Q1 2020 was ¥2,758,230.08, a decrease of 96.99% compared to ¥91,484,302.22 in the same period last year[8] - The net profit attributable to shareholders was -¥13,041,004.34, representing a 45.43% increase in losses compared to -¥8,966,936.17 in the previous year[8] - The net profit decreased by 44.47% to -¥13,053,465.20 from -¥9,035,125.01, reflecting reduced income and increased expenses[15] - The net loss for Q1 2020 was CNY 13,053,465.20, compared to a net loss of CNY 9,035,125.01 in Q1 2019, reflecting an increase in losses of approximately 44%[35] - The total comprehensive income for the parent company in Q1 2020 was -¥13,041,004.34, compared to -¥8,966,936.17 in Q1 2019, indicating a significant decline in overall performance[36] - Basic and diluted earnings per share for Q1 2020 were both -¥0.0169, worsening from -¥0.0116 in Q1 2019[36] Cash Flow and Liquidity - The net cash flow from operating activities was -¥4,790,684.39, which is a 63.16% improvement from -¥13,002,306.18 in the same period last year[8] - Cash and cash equivalents decreased by 66.27% to ¥27,197,614.66 from ¥80,644,820.58 due to loan repayments[15] - Cash received from sales dropped by 99.98% to ¥4,000.00 from ¥21,623,066.04, indicating no product sales during the quarter[15] - The company's cash and cash equivalents dropped from CNY 68,436,735.75 at the end of 2019 to CNY 14,980,430.44 by March 31, 2020, a decrease of about 78%[30] - The company reported a total cash outflow from financing activities of -¥48,005,077.36 in Q1 2020, compared to -¥16,172,991.27 in the same period last year, indicating increased cash outflows related to financing[44] - The cash received from other operating activities was 20,175.53 yuan, a notable increase from the previous period[45] Assets and Liabilities - The total assets at the end of the reporting period were ¥674,451,770.44, down 8.89% from ¥740,282,440.65 at the end of the previous year[8] - The total liabilities decreased from CNY 292,346,652.15 at the end of 2019 to CNY 239,569,447.14 by March 31, 2020, a reduction of about 18%[30] - The total equity attributable to shareholders decreased from CNY 441,936,607.51 at the end of 2019 to CNY 428,895,603.17 by March 31, 2020, a decline of approximately 3%[30] Operating Costs and Expenses - Operating costs decreased by 96.18% to ¥3,347,191.68 from ¥87,733,345.57, also due to factory shutdowns[15] - Management expenses increased by 35.12% to ¥11,382,896.18 from ¥8,424,348.49 due to costs associated with the shutdown[15] - The company incurred sales expenses of ¥20,832.67 in Q1 2020, up from ¥2,220.00 in Q1 2019, indicating increased costs associated with sales efforts[38] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,804[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., held 16.18% of the shares[10] Other Information - The company reported no non-recurring gains or losses during the reporting period[8] - The company did not undergo an audit for the first quarter report[48] - The company has not applied new revenue and leasing standards for the current reporting period[48]
中基健康(000972) - 2021 Q1 - 季度财报
2021-10-28 16:00
Financial Performance - The company's operating revenue for Q1 2021 was 0.00, a decrease of 100.00% compared to 2,758,230.08 in the same period last year[8] - The net profit attributable to shareholders was -19,979,751.27, representing an increase of 53.21% from -13,041,004.34 year-on-year[8] - The basic earnings per share were -0.0259, a decline of 53.25% from -0.0169 in the same period last year[8] - The total profit loss increased by 53.13% to ¥-19,988,180.25 compared to ¥-13,053,465.20 in the previous year, reflecting the ongoing transformation and production halt[15] - The net profit for Q1 2021 was a loss of CNY 19,988,180.25, compared to a loss of CNY 13,053,465.20 in the same period last year, indicating an increase in losses of about 53.5%[39] - The total operating costs for Q1 2021 were CNY 20,017,428.02, an increase from CNY 15,920,524.82 in the previous year, representing a growth of approximately 25.8%[38] Cash Flow and Liquidity - The net cash flow from operating activities was -25,390,802.51, an increase of 430.00% compared to -4,790,684.39 in the previous year[8] - The cash inflow from operating activities totaled CNY 149,553.82 in Q1 2021, a decrease from CNY 733,296.72 in the previous year[45] - Total cash outflow from operating activities amounted to 25,540,356.33 CNY, while cash inflow was only 1,581,660.56 CNY, resulting in a negative cash flow situation[49] - The ending cash and cash equivalents balance decreased to 10,548,551.53 CNY from 37,016,403.17 CNY at the beginning of the period, indicating a cash depletion of 26,467,851.64 CNY[47] - The company’s cash and cash equivalents decreased significantly from CNY 366,012.44 to CNY 16,884.87, a decline of approximately 95.4%[32] - The company’s cash and cash equivalents decreased by 71.32% to ¥10,613,891.89 from ¥37,007,442.78 due to a transformation and production halt[15] Assets and Liabilities - The total assets at the end of the reporting period were 562,832,228.58, down 3.38% from 582,505,841.85 at the end of the previous year[8] - The total liabilities increased slightly from CNY 401,294,652.22 to CNY 401,609,219.20, an increase of about 0.8%[31] - The company’s total equity decreased from CNY 181,211,189.63 to CNY 161,223,009.38, a decline of approximately 11%[32] - The total current liabilities increased from CNY 245,683,431.85 to CNY 245,963,265.50, an increase of about 0.1%[31] - The total non-current assets slightly increased from CNY 361,212,417.84 to CNY 362,306,880.74, an increase of about 0.3%[30] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,156[10] - The top shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., held 16.18% of shares[10] Operational Changes - The company is currently undergoing a transformation and production halt, impacting all major financial metrics significantly[15] - Management expenses increased by 63.99% to ¥18,666,259.97, attributed to fixed asset depreciation[15] - The company reported no non-recurring gains or losses during the reporting period[8] - The company did not report any cash inflow from investment activities, highlighting a lack of investment recovery during the quarter[50] - The company reported a credit impairment loss of CNY 25,000.00 in Q1 2021, compared to no such loss in the previous year[38] Tax and Financial Expenses - The company reported a 260.97% increase in tax payments to ¥9,401,699.46, due to tax liabilities from December 2020[17] - The financial expenses for Q1 2021 were CNY 1,345,108.05, up from CNY 1,072,145.61 in the previous year, indicating an increase of about 25.3%[38]
中基健康(000972) - 2021 Q3 - 季度财报
2021-10-28 16:00
Financial Performance - The company's operating revenue for the third quarter was ¥4,233,801.45, a decrease of 90.15% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥8,548,581.94, with a year-to-date loss of ¥54,849,067.67, representing a 30.35% increase in losses year-on-year[4] - Total operating revenue for the period was CNY 7,359,465.17, a decrease of 83.93% compared to CNY 45,786,377.20 in the previous period[20] - The net profit for Q3 2021 was a loss of CNY 54,876,089.09, compared to a loss of CNY 42,112,313.51 in the previous year, reflecting a worsening financial position[22] - The total comprehensive income for the period was a loss of CNY 54,876,089.09, compared to a loss of CNY 42,112,313.51 in the same quarter last year[22] - Basic and diluted earnings per share were both reported at CNY -0.0711, compared to CNY -0.0546 in the previous year[22] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was -¥260,820,543.21, an increase of 8,900.39% compared to the previous year[4] - Cash received from operating activities decreased by 75.85% to ¥12,072,906.77 compared to the previous year[8] - The cash flow from operating activities showed a net outflow of CNY 260,820,543.21, compared to a smaller outflow of CNY 2,897,879.20 in the same quarter last year[25] - The company reported a cash inflow from financing activities of CNY 275,587,666.68, a significant increase from a cash outflow of CNY 48,005,077.36 in the previous year[26] - The company’s cash and cash equivalents at the end of the period totaled CNY 50,547,571.13, an increase from CNY 26,646,992.28 at the end of the previous year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥863,303,440.02, an increase of 48.21% from the end of the previous year[4] - The company reported a total liability of CNY 736,968,339.48, compared to CNY 401,294,652.22 in the previous year[18] - Current assets totaled CNY 534,939,116.31, significantly up from CNY 221,293,424.01 at the end of 2020[16] - Total current liabilities rose to CNY 583,356,969.11 from CNY 245,683,431.85[18] - The company's equity attributable to shareholders decreased by 31.16% to ¥121,194,771.79 compared to the end of the previous year[4] - The company’s equity attributable to shareholders decreased to CNY 121,194,771.79 from CNY 176,043,839.46[18] Shareholder Information - The company had a total of 30,017 common shareholders at the end of the reporting period[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., holds 16.18% of the shares[10] Research and Development - Research and development expenses were reduced to ¥0.00 from ¥11,721,700.00 in the previous year, indicating a 100% decrease[7] - The company did not report any research and development expenses in Q3 2021, compared to CNY 11,721,700.00 in the same period last year[21] Operational Changes - The company reported a significant increase in accounts payable, which rose by 139.16% to ¥77,658,590.11 due to the resumption of production[7] - The total operating costs amounted to CNY 54,662,671.06, with operating costs specifically at CNY 7,873,335.63, down from CNY 17,470,147.34 year-over-year[21] - The company’s management expenses rose to CNY 40,941,641.91, up from CNY 36,853,759.11 year-over-year[21] - Inventory reached CNY 290,514,718.50, indicating a new addition as there was no inventory reported in the previous period[16] Legal and Regulatory Issues - The company is facing a court-ordered freeze on dividends amounting to CNY 123,970,926.36 for a period of three years[12]
中基健康(000972) - 2021 Q2 - 季度财报
2021-08-26 16:00
Financial Performance - The company's operating revenue for the first half of 2021 was ¥3,125,663.72, representing a 10.77% increase compared to ¥2,821,694.08 in the same period last year[21]. - The net profit attributable to shareholders was -¥46,300,485.73, slightly worse than -¥44,744,193.51 in the previous year[21]. - The net cash flow from operating activities was -¥18,531,697.98, compared to -¥6,808,897.15 in the same period last year[21]. - Total assets decreased by 7.53% to ¥538,653,747.66 from ¥582,505,841.85 at the end of the previous year[21]. - The net assets attributable to shareholders decreased by 26.30% to ¥129,743,353.73 from ¥176,043,839.46 at the end of the previous year[21]. - The weighted average return on net assets was -30.28%, an increase of 19.62 percentage points compared to -10.66% in the previous year[21]. - The company reported a net profit of -28.8 million for the period, indicating ongoing financial challenges[45]. - The company reported a total comprehensive loss of -46,321,199.04 CNY for the first half of 2021, compared to -44,769,204.53 CNY in the same period last year, representing an increase in losses of about 3.5%[113]. - The company's operating profit for the first half of 2021 was -46,982,640.85 CNY, compared to -44,833,816.31 CNY in the same period of 2020, indicating a decline of approximately 4.8%[113]. - The total liabilities as of June 30, 2021, amounted to CNY 403,763,757.07, slightly up from CNY 401,294,652.22 at the end of 2020[106]. Cash Flow and Liquidity - Cash and cash equivalents decreased significantly from CNY 37,007,442.78 to CNY 15,530,753.63, representing a decline of approximately 58.0%[103]. - The cash flow from operating activities for the first half of 2021 was -18,531,697.98 CNY, worsening from -6,808,897.15 CNY in the first half of 2020[120]. - The company had a cash and cash equivalents balance of 15,530,253.63 CNY at the end of the first half of 2021, down from 24,707,597.07 CNY at the end of the same period in 2020, a decrease of approximately 37.1%[121]. - The company reported a total cash outflow from investing activities of 214,751.73 yuan, compared to 5,003,000.00 yuan in the first half of 2020, reflecting a significant reduction in investment spending[124]. - The company's cash flow from operating activities showed a significant decrease in cash inflow from 488,111.74 yuan in the first half of 2020 to 10,259,380.76 yuan in the first half of 2021[123]. Operational Strategy and Future Plans - The company has initiated the recovery of tomato production and is organizing production work to gradually restore factory output and cost plans[28]. - The company plans to gradually restore production in its tomato industry, with expectations of improved market conditions for tomato sauce in the future[47]. - The company aims to optimize its product structure by focusing on high-value tomato lycopene health products[47]. - The company is committed to improving its capital operation efficiency and exploring long-term incentive mechanisms for employees[48]. - The company plans to enhance resource integration and reduce burdens by leasing assets, specifically through a contract for 87 tomato harvesters[80]. - The company aims to enhance its talent training system and recruitment mechanisms to improve management levels and overall employee quality[156]. Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period was 31,341[90]. - The largest shareholder, Xinjiang Production and Construction Corps, holds 16.18% of the shares, totaling 124,769,223 shares[90]. - The total number of shares remains at 771,283,579, with no changes reported[88]. - The total equity attributable to the parent company decreased to CNY 129,743,353.73 from CNY 176,043,839.46 at the end of 2020, reflecting a decline of approximately 26.3%[106]. - The company reported a total of CNY 540,843,097.79 in other receivables as of June 30, 2021, down from CNY 546,630,845.03 at the end of 2020[109]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding its future plans and projections[5]. - The company has faced significant operational risks due to adverse weather conditions affecting tomato production[46]. - The company has fulfilled all commitments made by its actual controllers, shareholders, and related parties during the reporting period[62]. - There are no non-operating fund occupations by controlling shareholders or other related parties during the reporting period[63]. - The company has no violations regarding external guarantees during the reporting period[64]. - The semi-annual financial report has not been audited[65]. Corporate Governance and Social Responsibility - The company is committed to enhancing the leadership role of the Party in state-owned enterprises and improving corporate governance to ensure sustainable development[155]. - The company actively participates in social responsibility initiatives, including poverty alleviation and supporting local agricultural development[58]. - The company emphasizes environmental protection and energy conservation as part of its operational strategy[58].
中基健康(000972) - 2021 Q1 - 季度财报
2021-04-29 16:00
Financial Performance - The company's operating revenue for Q1 2021 was 0.00, a decrease of 100.00% compared to 2,758,230.08 in the same period last year[8] - The net profit attributable to shareholders was -19,979,751.27, representing an increase in loss of 53.21% from -13,041,004.34 year-on-year[8] - The net cash flow from operating activities was -25,390,802.51, which is a significant decline of 430.00% compared to -4,790,684.39 in the previous year[8] - The basic earnings per share were -0.0259, a decrease of 53.25% from -0.0169 in the same period last year[8] - The total profit loss increased by 53.13% to ¥-19,988,180.25 compared to ¥-13,053,465.20 in the previous year, indicating ongoing financial challenges[15] - The total comprehensive loss for Q1 2021 was CNY 19,988,180.25, compared to a loss of CNY 13,053,465.20 in the same period last year, marking an increase in losses of approximately 53.5%[40] Assets and Liabilities - The total assets at the end of the reporting period were 562,832,228.58, down 3.38% from 582,505,841.85 at the end of the previous year[8] - The net assets attributable to shareholders decreased by 11.35% to 156,064,088.19 from 176,043,839.46 at the end of the previous year[8] - Total liabilities increased slightly from CNY 401,294,652.22 to CNY 401,609,219.20, reflecting a growth of about 0.8%[31] - The company's total equity decreased from CNY 181,211,189.63 to CNY 161,223,009.38, representing a decline of approximately 11%[32] Cash Flow - The company's cash and cash equivalents decreased by 71.32% to ¥10,613,891.89 from ¥37,007,442.78 due to a transformation and production halt[15] - Cash inflows from operating activities totaled CNY 149,553.82, a significant decrease from CNY 733,296.72 in the previous year[45] - The net cash flow from investing activities was -732,049.14 CNY, with no cash inflow recorded from investment activities[46] - The net cash flow from financing activities was -344,999.99 CNY, compared to -48,005,077.36 CNY in the previous period, showing a reduction in cash outflow related to financing[47] - The ending balance of cash and cash equivalents was 10,548,551.53 CNY, down from 26,161,078.33 CNY in the previous period, indicating a decrease in liquidity[47] Operational Challenges - Operating revenue dropped to ¥0.00, a 100% decrease compared to ¥2,758,230.08 in the previous year, as the company is in a transformation and production halt[15] - Management expenses increased by 63.99% to ¥18,666,259.97, primarily due to fixed asset depreciation[15] - The company reported no non-recurring gains or losses during the reporting period[8] - The company incurred a credit impairment loss of CNY 25,000.00, compared to no losses in the previous year[39] - The company has been actively communicating with investors, responding to over 50 inquiries regarding production and operational status during the reporting period[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,156[10] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., Ltd., holds 16.18% of the shares[10] Miscellaneous - The company has not engaged in any securities or derivative investments during the reporting period[20][21] - The company did not report any cash inflow from investment activities, indicating a lack of new investments during the period[48] - The company has not undergone an audit for the first quarter report, which may affect the reliability of the financial data presented[51]